Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma

Author:

Halwani Ahmad S.1,Panizo Carlos2,Isufi Iris3,Herrera Alex F.4,Okada Craig Y.5,Cull Elizabeth H.6,Kis Bela7,Chaves Jorge M.8,Bartlett Nancy L.9ORCID,Ai Weiyun10,de la Cruz-Merino Luis1112,Bryan Locke J.13,Houot Roch14,Linton Kim15,Briones Javier16,Chau Ian17,von Keudell Gottfried R.18,Lu Hailing19,Yakovich Adam19,Chen Michael19,Meulen JH ter1920,Yurasov Sergey19,Hsu Frank J.19,Flowers Christopher R.2122ORCID

Affiliation:

1. Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA

2. Department of Hematology and Hemotherapy, Clínica Universidad de Navarra; Instituto de Investigación Sanitaria de Navarra, University of Navarra, Pamplona, Spain

3. Department of Medicine (Hematology), Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA

4. Department of Hematology & Hematopoietic Cell Transportation, City of Hope Comprehensive Cancer Center, Duarte, CA, USA

5. Division of Hematology and Hematologic Malignancies, Oregon Health and Science University, Portland, OR, USA

6. Medical Oncology and Hematology Oncology, Prisma Health, Greenville, SC, USA

7. Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, FL, USA

8. Medical Oncology, Northwest Medical Specialties, Tacoma, WA, USA

9. Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA

10. Department of Medicine (Hematology/Oncology), Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA

11. Department of Clinical Oncology, Hospital Universitario Virgen Macarena, Seville, Spain

12. Department of Medicine, University of Seville, Seville, Spain

13. Department of Medicine, Augusta University, Augusta, GA, USA

14. Department of Hematology, CHU Rennes, University of Rennes, Rennes, France

15. Medical Oncology, The Christie NHS Foundation Trust & The University of Manchester, Manchester, United Kingdom

16. Department of Hematology, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain

17. Lymphoma Unit, Royal Marsden Hospital, London & Surrey, United Kingdom

18. Medical Oncology, Memorial Sloan Kettering Cancer Center, New York City, NY, USA

19. Immune Design, South San Francisco, CA, USA

20. Obsidian Therapeutics, Inc., Cambridge, MA, USA

21. Winship Cancer Institute, Emory University, Atlanta, GA, USA

22. CPRIT Scholar in Cancer Research, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Funder

Immune Design Corp., a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3